Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib + Anlotinib in EGFR+ Advanced NSCLC
NCT04028778Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04028778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04028778.